SAN DIEGO, May 21, 2024 ’ Erasca Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company specializing in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, has successfully concluded its oversubscribed underwritten offering. The company announced the closure of this offering, which included the full exercise of the underwriters’ option to purchase additional shares, resulting in the sale of 99,459,458 shares of its common stock. Priced at $1.85 per share, the gross proceeds to Erasca from this offering amounted to approximately $184.0 million.
Erasca’s primary focus is on developing innovative treatment solutions for patients with RAS/MAPK pathway-driven cancers, a broad range of aggressive malignancies that have been historically challenging to treat effectively. By capitalizing on precision oncology, Erasca aims to revolutionize cancer care by targeting the underlying genetic abnormalities that drive tumor growth.
This successful underwritten offering demonstrates the market’s confidence in Erasca’s mission and potential to address unmet medical needs in oncology. The oversubscription highlights the strong demand from investors who share Erasca’s vision of transforming cancer treatment through precision medicine.
The offering featured 12,972,972 additional shares, exercising the underwriters’ option in full. Erasca sold all the shares in this offering, streamlining its financial position and bolstering its resources to advance critical research and development efforts. The gross proceeds, before deducting underwriting discounts, commissions, and expenses associated with the offering, will be allocated to advancing Erasca’s portfolio of proprietary therapeutics.
Dr. Jonathan E. Lim, the Chairman, and CEO of Erasca, expressed his gratitude for the support received during the offering. He further emphasized the significance of this achievement in propelling Erasca closer to its goal of offering novel cancer treatments.
Closing this oversubscribed underwritten offering is an important milestone for Erasca, as it demonstrates the market’s recognition of our groundbreaking approach to precision oncology, said Dr. Lim. We are grateful for the trust and confidence placed in Erasca by our investors and remain committed to utilizing these resources to rapidly advance our pipeline of innovative therapies.
With the proceeds from this underwritten offering, Erasca plans to continue its research and clinical development activities focused on investigating novel treatments that selectively target the RAS/MAPK pathway. Erasca’s pioneering approach involves utilizing small molecule inhibitors and other therapeutics designed to interfere with the specific genetic drivers implicated in RAS/MAPK pathway-driven cancers.
By successfully completing this underwritten offering, Erasca has further solidified its financial position and reinforced its commitment to addressing the urgent needs of patients with RAS/MAPK pathway-driven cancers. Through a multidimensional approach combining biological insights, advanced computational algorithms, and drug development expertise, Erasca aspires to make a positive impact on the lives of cancer patients worldwide.
Comments